WSE:IST

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Infoscan S.A. provides equipment for the remote diagnostics and monitoring of breathing disorders during sleep. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Infoscan's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IST is not significantly more volatile than the rest of Polish stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: IST's weekly volatility has decreased from 16% to 11% over the past year.


Market Performance


7 Day Return

-7.7%

IST

2.6%

PL Medical Equipment

-1.2%

PL Market


1 Year Return

-41.8%

IST

865.1%

PL Medical Equipment

-4.4%

PL Market

Return vs Industry: IST underperformed the Polish Medical Equipment industry which returned 841.5% over the past year.

Return vs Market: IST underperformed the Polish Market which returned -6.5% over the past year.


Shareholder returns

ISTIndustryMarket
7 Day-7.7%2.6%-1.2%
30 Day6.9%-2.3%16.8%
90 Day-17.9%21.2%2.5%
1 Year-41.8%-41.8%866.1%865.1%-3.5%-4.4%
3 Year-85.9%-85.9%291.8%289.2%-15.7%-20.9%
5 Year-82.4%-82.4%222.5%217.5%6.9%-5.1%

Long-Term Price Volatility Vs. Market

How volatile is Infoscan's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Infoscan undervalued compared to its fair value and its price relative to the market?

5.14x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: IST (PLN0.86) is trading above our estimate of fair value (PLN0.67)

Significantly Below Fair Value: IST is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: IST is unprofitable, so we can't compare its PE Ratio to the XE Medical Equipment industry average.

PE vs Market: IST is unprofitable, so we can't compare its PE Ratio to the Polish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IST's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IST is overvalued based on its PB Ratio (5.1x) compared to the PL Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is Infoscan forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

58.0%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if IST's forecast earnings growth is above the savings rate (2.9%).

Earnings vs Market: Insufficient data to determine if IST's earnings are forecast to grow faster than the Polish market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: IST's revenue (58% per year) is forecast to grow faster than the Polish market (7% per year).

High Growth Revenue: IST's revenue (58% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IST's Return on Equity is forecast to be low in 3 years time (15.9%).


Next Steps

Past Performance

How has Infoscan performed over the past 5 years?

-4.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IST is currently unprofitable.

Growing Profit Margin: IST is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IST is unprofitable, and losses have increased over the past 5 years at a rate of 4.8% per year.

Accelerating Growth: Unable to compare IST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IST is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-4.6%).


Return on Equity

High ROE: IST has a negative Return on Equity (-108.65%), as it is currently unprofitable.


Next Steps

Financial Health

How is Infoscan's financial position?


Financial Position Analysis

Short Term Liabilities: IST's short term assets (PLN5.1M) exceed its short term liabilities (PLN3.2M).

Long Term Liabilities: IST has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: IST is debt free.

Reducing Debt: IST had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IST has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IST has less than a year of cash runway if free cash flow continues to reduce at historical rates of 19.6% each year


Next Steps

Dividend

What is Infoscan current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IST's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IST's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average board tenure


CEO

Infoscan has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Jerzy Kowalski
Member of the Supervisory Boardno datano datano data
Pawel Janiszewski
President of the Supervisory Boardno datano datano data
Dariusz Glogowski
Member of Supervisory Board0.83yrno datano data
Tomasz Nowowiejski
Member of Supervisory Board1.08yrsno datano data
Maria Skowronska
Member of the Supervisory Board1.83yrsno datano data
Zbigniew Gaciong
Member of the Supervisory Boardno datano datano data

1.1yrs

Average Tenure

Experienced Board: IST's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 83.3%.


Top Shareholders

Company Information

Infoscan S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Infoscan S.A.
  • Ticker: IST
  • Exchange: WSE
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: zł7.944m
  • Shares outstanding: 9.03m
  • Website: https://www.infoscan.pl

Number of Employees


Location

  • Infoscan S.A.
  • ul. Rejtana 17/16
  • Warsaw
  • 02-516
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ISTWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNApr 2015

Biography

Infoscan S.A. provides equipment for the remote diagnostics and monitoring of breathing disorders during sleep. It offers MED Recorder, a device that enables examination of disorders occurring during sleep...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/01 18:04
End of Day Share Price2020/12/01 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.